---
document_datetime: 2025-12-02 05:35:56
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/sivextro.html
document_name: sivextro.html
version: success
processing_time: 0.1147249
conversion_datetime: 2025-12-27 20:57:12.623905
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Sivextro

[RSS](/en/individual-human-medicine.xml/65753)

##### Authorised

This medicine is authorised for use in the European Union

tedizolid phosphate Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Sivextro](#news-on)
- [More information on Sivextro](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Sivextro is an antibiotic used in adults, adolescents and children to treat acute (short-term) bacterial infections of the skin and skin structures (tissue below the skin) such as cellulitis (infection of the skin and the tissue underneath), skin abscesses (a swollen area on the skin where pus has collected) and wound infections.

Sivextro contains the active substance tedizolid.

Expand section

Collapse section

## How is Sivextro used?

Sivextro can only be obtained with a prescription, and prescribers should consider official guidance on the appropriate use of antibiotics.

Sivextro is given as an infusion (drip) into a vein; for adults, adolescents and children weighing at least 35 kg, it is also available as tablets to be taken by mouth. Adults, adolescents and children weighing at least 35 kg who are started on the infusion may be switched to the tablets when appropriate. The duration of treatment is 6 days.

For more information about using Sivextro, see the package leaflet or contact your doctor or pharmacist.

## How does Sivextro work?

The active substance in Sivextro, tedizolid, is a type of antibiotic called an oxazolidinone. It works by preventing certain bacteria from making proteins, thereby stopping their growth. Sivextro has been shown to work mainly against bacteria called Gram-positive bacteria, including those for which standard antibiotics do not work, such as methicillin-resistant *Staphylococcus aureus* (MRSA).

## What benefits of Sivextro have been shown in studies?

Sivextro was at least as effective as linezolid (another oxazolidinone antibiotic) in two main studies involving a total of 1,333 adults with acute bacterial infections of the skin and skin structures. These included infections caused by MRSA. The infection was cured in 85.5% of the patients treated with Sivextro in the first study and 88.0% in the second study, compared with 86.0% and 87.7%, respectively, of those treated with linezolid.

Two studies involving a total of 220 children and adolescents up to 18 years of age found that blood levels of Sivextro in these patients were similar to those seen in adults treated with the medicine. This is supported by data indicating that the effectiveness of Sivextro was comparable to that of other medicines in the treatment of acute bacterial infections of the skin and skin structures.

## What are the risks associated with Sivextro?

For the full list of side effects and restrictions of Sivextro, see the package leaflet.

In adults, the most common side effects with Sivextro (which may affect up to 1 in 10 people) include headache, nausea (feeling sick), vomiting and diarrhoea. In children, the most common side effects (which may affect up to 1 in 10 children) include nausea, vomiting and phlebitis (inflammation of a vein).

## Why is Sivextro authorised in the EU

The European Medicines Agency decided that Sivextro's benefits are greater than its risks and it can be authorised for use in the EU.

Although the infections in the studies involving adults were not severe, the Agency considered that the results also apply to severe infections. Because of the need for new antibiotics against bacteria that have become resistant to several antibiotics, especially those that can be given by mouth, the Agency considered Sivextro a valuable treatment option for bacterial infections of the skin and skin structures. Based on data from studies in children from birth to 18 years old, the medicine is also expected to be effective in treating such infections in children and adolescents. Sivextro's pattern of side effects is comparable to that of linezolid and was considered acceptable.

## What measures are being taken to ensure the safe and effective use of Sivextro?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sivextro have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Sivextro are continuously monitored. Side effects reported with Sivextro are carefully evaluated and any necessary action taken to protect patients.

## Other information about Sivextro

Sivextro received a marketing authorisation valid throughout the EU on 23 March 2015.

Sivextro : EPAR - Medicine overview

Reference Number: EMA/55036/2025

English (EN) (121.12 KB - PDF)

**First published:** 26/03/2015

**Last updated:** 20/03/2025

[View](/en/documents/overview/sivextro-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-624)

български (BG) (135.12 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/bg/documents/overview/sivextro-epar-medicine-overview_bg.pdf)

español (ES) (110.41 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/es/documents/overview/sivextro-epar-medicine-overview_es.pdf)

čeština (CS) (133.06 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/cs/documents/overview/sivextro-epar-medicine-overview_cs.pdf)

dansk (DA) (110.84 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/da/documents/overview/sivextro-epar-medicine-overview_da.pdf)

Deutsch (DE) (114.86 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/de/documents/overview/sivextro-epar-medicine-overview_de.pdf)

eesti keel (ET) (108.56 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/et/documents/overview/sivextro-epar-medicine-overview_et.pdf)

ελληνικά (EL) (142.69 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/el/documents/overview/sivextro-epar-medicine-overview_el.pdf)

français (FR) (112.83 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/fr/documents/overview/sivextro-epar-medicine-overview_fr.pdf)

hrvatski (HR) (132.8 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/hr/documents/overview/sivextro-epar-medicine-overview_hr.pdf)

italiano (IT) (109.84 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/it/documents/overview/sivextro-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (147.91 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/lv/documents/overview/sivextro-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (131.19 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/lt/documents/overview/sivextro-epar-medicine-overview_lt.pdf)

magyar (HU) (134.48 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/hu/documents/overview/sivextro-epar-medicine-overview_hu.pdf)

Malti (MT) (133.5 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/mt/documents/overview/sivextro-epar-medicine-overview_mt.pdf)

Nederlands (NL) (111.92 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/nl/documents/overview/sivextro-epar-medicine-overview_nl.pdf)

polski (PL) (136.54 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/pl/documents/overview/sivextro-epar-medicine-overview_pl.pdf)

português (PT) (110.92 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/pt/documents/overview/sivextro-epar-medicine-overview_pt.pdf)

română (RO) (137.17 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/ro/documents/overview/sivextro-epar-medicine-overview_ro.pdf)

slovenčina (SK) (133.19 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/sk/documents/overview/sivextro-epar-medicine-overview_sk.pdf)

slovenščina (SL) (130.56 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/sl/documents/overview/sivextro-epar-medicine-overview_sl.pdf)

Suomi (FI) (108.07 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/fi/documents/overview/sivextro-epar-medicine-overview_fi.pdf)

svenska (SV) (108.87 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/sv/documents/overview/sivextro-epar-medicine-overview_sv.pdf)

Sivextro : EPAR - Risk management plan

English (EN) (2.75 MB - PDF)

**First published:** 22/01/2019

**Last updated:** 20/03/2025

[View](/en/documents/rmp/sivextro-epar-risk-management-plan_en.pdf)

## Product information

Sivextro : EPAR - Product Information

English (EN) (513.77 KB - PDF)

**First published:** 26/03/2015

**Last updated:** 20/03/2025

[View](/en/documents/product-information/sivextro-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-234)

български (BG) (450.32 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/bg/documents/product-information/sivextro-epar-product-information_bg.pdf)

español (ES) (549.07 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/es/documents/product-information/sivextro-epar-product-information_es.pdf)

čeština (CS) (524.93 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/cs/documents/product-information/sivextro-epar-product-information_cs.pdf)

dansk (DA) (537.54 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/da/documents/product-information/sivextro-epar-product-information_da.pdf)

Deutsch (DE) (600.96 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/de/documents/product-information/sivextro-epar-product-information_de.pdf)

eesti keel (ET) (523.12 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/et/documents/product-information/sivextro-epar-product-information_et.pdf)

ελληνικά (EL) (472.72 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/el/documents/product-information/sivextro-epar-product-information_el.pdf)

français (FR) (586.68 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/fr/documents/product-information/sivextro-epar-product-information_fr.pdf)

hrvatski (HR) (516.87 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/hr/documents/product-information/sivextro-epar-product-information_hr.pdf)

íslenska (IS) (517.81 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/is/documents/product-information/sivextro-epar-product-information_is.pdf)

italiano (IT) (562.41 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/it/documents/product-information/sivextro-epar-product-information_it.pdf)

latviešu valoda (LV) (460.45 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/lv/documents/product-information/sivextro-epar-product-information_lv.pdf)

lietuvių kalba (LT) (511.01 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/lt/documents/product-information/sivextro-epar-product-information_lt.pdf)

magyar (HU) (604.51 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/hu/documents/product-information/sivextro-epar-product-information_hu.pdf)

Malti (MT) (551.98 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/mt/documents/product-information/sivextro-epar-product-information_mt.pdf)

Nederlands (NL) (559.32 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/nl/documents/product-information/sivextro-epar-product-information_nl.pdf)

norsk (NO) (524.28 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/no/documents/product-information/sivextro-epar-product-information_no.pdf)

polski (PL) (563.32 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/pl/documents/product-information/sivextro-epar-product-information_pl.pdf)

português (PT) (559.26 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/pt/documents/product-information/sivextro-epar-product-information_pt.pdf)

română (RO) (547.08 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/ro/documents/product-information/sivextro-epar-product-information_ro.pdf)

slovenčina (SK) (574.07 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/sk/documents/product-information/sivextro-epar-product-information_sk.pdf)

slovenščina (SL) (537.28 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/sl/documents/product-information/sivextro-epar-product-information_sl.pdf)

Suomi (FI) (549.31 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/fi/documents/product-information/sivextro-epar-product-information_fi.pdf)

svenska (SV) (538.38 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

20/03/2025

[View](/sv/documents/product-information/sivextro-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** II/0054 28/02/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Sivextro : EPAR - All Authorised presentations

English (EN) (52.71 KB - PDF)

**First published:** 26/03/2015

**Last updated:** 06/09/2016

[View](/en/documents/all-authorised-presentations/sivextro-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-192)

български (BG) (56.08 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

06/09/2016

[View](/bg/documents/all-authorised-presentations/sivextro-epar-all-authorised-presentations_bg.pdf)

español (ES) (52.01 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

06/09/2016

[View](/es/documents/all-authorised-presentations/sivextro-epar-all-authorised-presentations_es.pdf)

čeština (CS) (53.57 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

06/09/2016

[View](/cs/documents/all-authorised-presentations/sivextro-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (54.65 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

06/09/2016

[View](/da/documents/all-authorised-presentations/sivextro-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (54.94 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

06/09/2016

[View](/de/documents/all-authorised-presentations/sivextro-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (52.84 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

06/09/2016

[View](/et/documents/all-authorised-presentations/sivextro-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (55.12 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

06/09/2016

[View](/el/documents/all-authorised-presentations/sivextro-epar-all-authorised-presentations_el.pdf)

français (FR) (52.37 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

06/09/2016

[View](/fr/documents/all-authorised-presentations/sivextro-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (52.79 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

06/09/2016

[View](/hr/documents/all-authorised-presentations/sivextro-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (53.64 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

06/09/2016

[View](/is/documents/all-authorised-presentations/sivextro-epar-all-authorised-presentations_is.pdf)

italiano (IT) (52.02 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

06/09/2016

[View](/it/documents/all-authorised-presentations/sivextro-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (53.26 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

06/09/2016

[View](/lv/documents/all-authorised-presentations/sivextro-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (53.02 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

06/09/2016

[View](/lt/documents/all-authorised-presentations/sivextro-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (53.81 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

06/09/2016

[View](/hu/documents/all-authorised-presentations/sivextro-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (53.76 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

06/09/2016

[View](/mt/documents/all-authorised-presentations/sivextro-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (52.9 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

06/09/2016

[View](/nl/documents/all-authorised-presentations/sivextro-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (54.02 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

06/09/2016

[View](/no/documents/all-authorised-presentations/sivextro-epar-all-authorised-presentations_no.pdf)

polski (PL) (54.03 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

06/09/2016

[View](/pl/documents/all-authorised-presentations/sivextro-epar-all-authorised-presentations_pl.pdf)

português (PT) (53.13 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

06/09/2016

[View](/pt/documents/all-authorised-presentations/sivextro-epar-all-authorised-presentations_pt.pdf)

română (RO) (52.93 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

06/09/2016

[View](/ro/documents/all-authorised-presentations/sivextro-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (54.17 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

06/09/2016

[View](/sk/documents/all-authorised-presentations/sivextro-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (52.88 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

06/09/2016

[View](/sl/documents/all-authorised-presentations/sivextro-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (51.74 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

06/09/2016

[View](/fi/documents/all-authorised-presentations/sivextro-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (22.26 KB - PDF)

**First published:**

26/03/2015

**Last updated:**

06/09/2016

[View](/sv/documents/all-authorised-presentations/sivextro-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Sivextro International non-proprietary name (INN) or common name tedizolid phosphate Therapeutic area (MeSH)

- Soft Tissue Infections
- Skin Diseases, Bacterial

Anatomical therapeutic chemical (ATC) code J01XX11

### Pharmacotherapeutic group

- Antibacterials for systemic use
- Other antibacterials

### Therapeutic indication

Sivextro tablets are indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults, adolescents and children weighing at least 35 kg. Consideration should be given to official guidance on the appropriate use of antibacterial agents.

Sivextro powder for concentrate for solution for infusion is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) from birth.

Consideration should be given to official guidance on the appropriate use of antibacterial agents.

## Authorisation details

EMA product number EMEA/H/C/002846 Marketing authorisation holder

Merck Sharp &amp; Dohme B.V.

Waarderweg 39

Opinion adopted 22/01/2015 Marketing authorisation issued 23/03/2015 Revision 25

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Sivextro : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (244.52 KB - PDF)

**First published:** 05/06/2015

**Last updated:** 20/03/2025

[View](/en/documents/procedural-steps-after/sivextro-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Sivextro-H-C-002846-II-0054 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/63803/2025

English (EN) (8.11 MB - PDF)

**First published:** 20/03/2025

[View](/en/documents/variation-report/sivextro-h-c-002846-ii-0054-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Sivextro (II-54)

Adopted

Reference Number: EMA/CHMP/31360/2025

English (EN) (155.8 KB - PDF)

**First published:** 31/01/2025

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sivextro-ii-54_en.pdf)

Sivextro-H-C-PSUSA-00010369-202306 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation

Reference Number: EMA/186543/2024

English (EN) (167.06 KB - PDF)

**First published:** 03/05/2024

[View](/en/documents/scientific-conclusion/sivextro-h-c-psusa-00010369-202306-epar-scientific-conclusions-grounds-variation-terms-marketing-authorisation_en.pdf)

Sivextro-H-C-002846-P46-010 : EPAR - Assessment report

Reference Number: EMA/92459/2024

English (EN) (1.32 MB - PDF)

**First published:** 23/04/2024

[View](/en/documents/variation-report/sivextro-h-c-002846-p46-010-epar-assessment-report_en.pdf)

Sivextro-H-C-PSUSA-00010369-202006 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/176773/2021

English (EN) (169.72 KB - PDF)

**First published:** 25/03/2021

[View](/en/documents/scientific-conclusion/sivextro-h-c-psusa-00010369-202006-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

Sivextro-H-C-002846-II-0035 : EPAR - Assessment report - variation

Adopted

Reference Number: EMA/316574/2020

English (EN) (1.19 MB - PDF)

**First published:** 28/07/2020

[View](/en/documents/variation-report/sivextro-h-c-002846-ii-0035-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Sivextro (II-35)

Adopted

Reference Number: EMA/CHMP/269339/2020

English (EN) (135.95 KB - PDF)

**First published:** 29/05/2020

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sivextro-ii-35_en.pdf)

## Initial marketing authorisation documents

Sivextro : EPAR - Public assessment report

Adopted

Reference Number: EMA/83337/2015

English (EN) (2.31 MB - PDF)

**First published:** 26/03/2015

**Last updated:** 26/03/2015

[View](/en/documents/assessment-report/sivextro-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Sivextro

Adopted

Reference Number: EMA/CHMP/46218/2015

English (EN) (69.44 KB - PDF)

**First published:** 23/01/2015

**Last updated:** 23/01/2015

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-sivextro_en.pdf)

#### News on Sivextro

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 27-30 January 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-30-january-2025) 31/01/2025

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 May 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-may-2020) 29/05/2020

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 January 2015](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-january-2015) 23/01/2015

#### More information on Sivextro

- [EMEA-001379-PIP01-12-M08 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-001379-pip01-12-m08)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 20/03/2025

## Share this page

[Back to top](#main-content)